Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

ABSTRACT:

Background

Brain volume loss (BVL) has been identified as a predictor of disability progression in relapsing multiple sclerosis (RMS). As many available disease-modifying treatments (DMTs) have shown an effect on slowing BVL, this is becoming an emerging clinical endpoint in RMS clinical trials.

Methods

In this study, a systematic literature review was conducted to identify BVL results from randomized controlled trials of DMTs in RMS. Indirect treatment comparisons (ITCs) were conducted to estimate the relative efficacy of DMTs on BVL using two approaches: a model-based meta-analysis (MBMA) with adjustment for measurement timepoint and DMT dosage, and a network meta-analysis (NMA).

Results

In the MBMA, DMTs associated with significantly reduced BVL versus placebo at t

SUBMITTER: Zivadinov R 

PROVIDER: S-EPMC11460132 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature